LUC00278I2 - - Google Patents
Download PDFInfo
- Publication number
- LUC00278I2 LUC00278I2 LU00278C LUC00278C LUC00278I2 LU C00278 I2 LUC00278 I2 LU C00278I2 LU 00278 C LU00278 C LU 00278C LU C00278 C LUC00278 C LU C00278C LU C00278 I2 LUC00278 I2 LU C00278I2
- Authority
- LU
- Luxembourg
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0911566.8A GB0911566D0 (en) | 2009-07-03 | 2009-07-03 | T cell receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LUC00278I2 true LUC00278I2 (enExample) | 2025-05-12 |
Family
ID=41008692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU00278C LUC00278I2 (enExample) | 2009-07-03 | 2022-09-05 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8519100B2 (enExample) |
| EP (1) | EP2448963B1 (enExample) |
| JP (2) | JP5872464B2 (enExample) |
| CN (3) | CN102574906A (enExample) |
| AU (1) | AU2010267758C1 (enExample) |
| BR (1) | BR112012000107A2 (enExample) |
| CA (1) | CA2766505C (enExample) |
| DK (1) | DK2448963T3 (enExample) |
| EA (1) | EA026918B1 (enExample) |
| ES (1) | ES2498190T3 (enExample) |
| FI (1) | FIC20220037I1 (enExample) |
| FR (1) | FR22C1046I2 (enExample) |
| GB (1) | GB0911566D0 (enExample) |
| LU (1) | LUC00278I2 (enExample) |
| MX (1) | MX2012000155A (enExample) |
| NL (1) | NL301193I2 (enExample) |
| PT (1) | PT2448963E (enExample) |
| WO (1) | WO2011001152A1 (enExample) |
| ZA (1) | ZA201109522B (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| US12492376B2 (en) | 2009-10-29 | 2025-12-09 | The Trustees Of Dartmouth College | T-cell receptor-deficient T cell compositions |
| US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| JP2014530009A (ja) * | 2011-09-29 | 2014-11-17 | エーピーオー‐ティー ビー．ヴイ． | 異常細胞を標的とする多重特異性結合分子 |
| EP2802356A1 (en) | 2012-01-13 | 2014-11-19 | Apo-T B.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
| US9790278B2 (en) | 2012-05-07 | 2017-10-17 | The Trustees Of Dartmouth College | Anti-B7-H6 antibody, fusion proteins, and methods of using the same |
| EP2897631A4 (en) | 2012-08-31 | 2016-10-05 | Univ Virginia Patent Found | TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS |
| AU2013312529A1 (en) | 2012-09-05 | 2015-04-16 | The University Of Birmingham | Target peptides for colorectal cancer therapy and diagnostics |
| GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| WO2014118236A2 (en) | 2013-01-29 | 2014-08-07 | Max-Delbrück-Centrum Für Moledulare Medizin (Mdc) Berlin-Buch | High avidity antigen recognizing constructs |
| WO2014206304A1 (zh) * | 2013-06-26 | 2014-12-31 | 广州市香雪制药股份有限公司 | 高稳定性的t细胞受体及其制法和应用 |
| WO2015077615A1 (en) * | 2013-11-22 | 2015-05-28 | The Board Of Trustees Of The University Of Illinois | Engineered high-affinity human t cell receptors |
| DE202014002754U1 (de) | 2014-03-31 | 2015-07-03 | Christian Piotrowski | Ausgusssystem mit Pullring der mit der Folie verbunden ist. |
| CA2945816A1 (en) | 2014-04-15 | 2015-10-22 | University Of Virginia Patent Foundation | Isolated t cell receptors and methods of use therefor |
| CN106459176B (zh) * | 2014-06-18 | 2018-07-06 | 广东香雪精准医疗技术有限公司 | 高亲和力hcv t细胞受体 |
| CA2955984A1 (en) | 2014-07-22 | 2016-01-28 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
| EP3177314B1 (en) * | 2014-08-04 | 2020-10-07 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
| AU2014407539B2 (en) * | 2014-10-02 | 2020-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation |
| GB201417803D0 (en) * | 2014-10-08 | 2014-11-19 | Adaptimmune Ltd | T cell receptors |
| JP7372728B2 (ja) * | 2014-10-31 | 2023-11-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改変ｔ細胞に関する方法および組成物 |
| EP3215164A1 (en) | 2014-11-03 | 2017-09-13 | Immures S.r.l. | T cell receptors |
| GB201506642D0 (en) * | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| CN108026171A (zh) * | 2015-06-01 | 2018-05-11 | 基因医疗免疫疗法有限责任公司 | T细胞受体特异性抗体 |
| HK1253694A1 (zh) * | 2015-06-01 | 2019-06-28 | Medigene Immunotherapies Gmbh | T细胞受体文库 |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201516272D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
| GB201516277D0 (en) * | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR libraries |
| ES2968802T3 (es) | 2016-03-16 | 2024-05-14 | Immatics Biotechnologies Gmbh | Células T transfectadas y receptores de células T para su uso en inmunoterapia contra el cáncer |
| LT3430037T (lt) | 2016-03-16 | 2022-12-12 | Immatics Biotechnologies Gmbh | Transfekuotos t ląstelės ir t ląstelių receptoriai, skirti naudoti vėžio gydymui taikant imunoterapiją |
| GB201604953D0 (en) | 2016-03-23 | 2016-05-04 | Immunocore Ltd | T cell receptors |
| RU2736512C2 (ru) | 2016-03-28 | 2020-11-17 | Дау Глоубл Текнолоджиз Ллк | Двухкомпонентные адгезивные композиции, не содержащие растворителя, и способы их получения |
| SI3464380T1 (sl) | 2016-06-02 | 2025-03-31 | Immunocore Limited | Režim doziranja za gp100-specifični tcr - anti-cd3 scfv fuzijski protein |
| NZ750479A (en) | 2016-08-17 | 2021-12-24 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same |
| DE102016115246C5 (de) | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| JP2020501508A (ja) * | 2016-09-15 | 2020-01-23 | クアドルセプト バイオ リミテッド | 多量体、四量体および八量体 |
| GB201617714D0 (en) | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
| JP7037577B2 (ja) | 2017-03-15 | 2022-03-16 | フレッド ハッチンソン キャンサー リサーチ センター | 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 |
| DE102017106305A1 (de) | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
| GB201709866D0 (en) * | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
| MX2020003144A (es) * | 2017-09-22 | 2020-07-28 | Wuxi Biologics Ireland Ltd | Nuevos complejos de polipeptidos biespecificos cd3/cd19. |
| KR102839644B1 (ko) | 2017-09-22 | 2025-07-31 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 이중특이적 폴리펩티드 복합체 |
| US20200308279A1 (en) | 2017-10-06 | 2020-10-01 | Oslo Universitetssykehus Hf | Chimeric antigen receptors |
| CN109776671B (zh) * | 2017-11-14 | 2022-05-27 | 杭州康万达医药科技有限公司 | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 |
| US20210371849A1 (en) * | 2018-07-31 | 2021-12-02 | Janux Therapeutics, Inc. | Inhibitory t cell receptor peptides and discovery methods |
| JP7558151B2 (ja) * | 2018-09-05 | 2024-09-30 | アダプティミューン・リミテッド | Ｔ細胞改変 |
| DK3911298T3 (da) | 2019-01-17 | 2024-01-29 | Immunocore Ltd | Formuleringer |
| GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
| GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| GB201902277D0 (en) | 2019-02-19 | 2019-04-03 | King S College London | Therapeutic agents |
| WO2020247871A2 (en) * | 2019-06-06 | 2020-12-10 | Janux Therapeutics, Inc. | Compositions and methods relating to tumor activated t cell engagers |
| TW202118781A (zh) * | 2019-07-30 | 2021-05-16 | 大學健康網絡 | Ｉｉ類ｍｈｃ分子及其使用方法 |
| CN111234004B (zh) * | 2020-02-28 | 2023-03-28 | 陕西九州新药评价研究有限公司(西安新药评价研究中心) | 识别wt1抗原短肽的t细胞受体及其应用 |
| GB202006629D0 (en) * | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| WO2021236548A1 (en) * | 2020-05-18 | 2021-11-25 | Board Of Regents, The University Of Texas System | Engineered t cell receptors and methods of use |
| CN112239495B (zh) * | 2020-10-29 | 2022-04-12 | 上海药明生物技术有限公司 | 稳定的tcr结构及应用 |
| CN114853879A (zh) * | 2021-02-03 | 2022-08-05 | 香雪生命科学技术（广东）有限公司 | 一种识别hpv的t细胞受体 |
| WO2022258606A1 (en) | 2021-06-07 | 2022-12-15 | Gadeta B.V. | Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response |
| US12103971B2 (en) | 2022-02-20 | 2024-10-01 | Immunocore Limited | HIV specific binding molecules |
| WO2023227594A1 (en) | 2022-05-24 | 2023-11-30 | Gadeta Bv | Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof |
| WO2023237541A1 (en) | 2022-06-07 | 2023-12-14 | Gadeta B.V. | Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response |
| WO2023246911A1 (zh) * | 2022-06-24 | 2023-12-28 | 北京可瑞生物科技有限公司 | 基于t细胞受体的双特异性多肽分子及其用途 |
| US20240075068A1 (en) | 2022-07-15 | 2024-03-07 | Gadeta B.V. | Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response |
| CA3264727A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | MULTI-DOMAIN BONDING MOLECULES |
| AU2023326819A1 (en) | 2022-08-18 | 2025-03-06 | Immunocore Limited | Multi-domain binding molecules |
| AU2023326804A1 (en) | 2022-08-18 | 2025-03-06 | Immunocore Limited | Multi-domain binding molecules |
| WO2024067821A1 (zh) * | 2022-09-30 | 2024-04-04 | 瑅安生物医药（杭州）有限公司 | 一种修饰细胞及其用途 |
| EP4634216A1 (en) | 2022-12-16 | 2025-10-22 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| WO2024260454A1 (zh) * | 2023-06-21 | 2024-12-26 | 北京可瑞生物科技有限公司 | 经修饰的tcr恒定区及其在tcr融合蛋白中的用途 |
| GB202315181D0 (en) | 2023-10-03 | 2023-11-15 | Immunocore Ltd | Peptide-HLA binding molecules |
| TW202530269A (zh) * | 2023-10-27 | 2025-08-01 | 大陸商北京可瑞生物科技有限公司 | 基於ｔ細胞受體的多特異性多肽分子及其組合物和用途 |
| WO2025094054A1 (en) | 2023-11-01 | 2025-05-08 | Immunocore Limited | Method for purifying small multi-domain proteins |
| GB202320012D0 (en) | 2023-12-22 | 2024-02-07 | Immunocore Ltd | Bispecific molecules |
| CN118108833B (zh) * | 2024-03-12 | 2025-05-02 | 缇纱(合肥)生物技术有限公司 | 引入外源二硫键的tcr恒定区及其产品和应用 |
| WO2025224692A1 (en) | 2024-04-25 | 2025-10-30 | Immunocore Limited | Method of treating cancer using a gene expression signature |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688747A (en) | 1994-08-22 | 1997-11-18 | Becton Dickinson And Company | Water based lubricant solution |
| US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
| NZ507886A (en) * | 1998-05-19 | 2003-05-30 | Avidex Ltd | Multivalent T cell receptor complexes |
| CA2457652C (en) * | 2001-08-31 | 2012-08-07 | Avidex Limited | Soluble t cell receptor |
| WO2004044004A2 (en) | 2002-11-09 | 2004-05-27 | Avidex Limited | T cell receptor display |
| GB0227351D0 (en) * | 2002-11-22 | 2002-12-31 | Isis Innovation | Soluble T-cell receptors |
| US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| CN101035561A (zh) * | 2004-03-24 | 2007-09-12 | 特罗斯药品公司 | 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法 |
| GB0411125D0 (en) * | 2004-05-19 | 2004-06-23 | Avidex Ltd | Method of improving T-cell receptors |
| JP4972549B2 (ja) | 2004-05-19 | 2012-07-11 | イムノコア リミテッド | Ｔ細胞レセプターを改善する方法 |
| ATE475669T1 (de) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
| US20060045884A1 (en) * | 2004-08-26 | 2006-03-02 | Board Of Regents | Vaccines for autoimmune and infectious disease |
| CA2580412A1 (en) * | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| WO2006054096A2 (en) * | 2004-11-18 | 2006-05-26 | Avidex Ltd | Soluble bifunctional proteins |
| ES2829566T3 (es) * | 2005-03-03 | 2021-06-01 | Immunomedics Inc | Anticuerpos L243 humanizados |
| GB0511124D0 (en) | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| EP1795599A1 (en) * | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
| PT2016102E (pt) | 2006-05-03 | 2012-05-15 | Us Gov Health & Human Serv | Recetores de célula t quimérica e materiais relacionados e métodos de uso |
| WO2008038002A2 (en) | 2006-09-29 | 2008-04-03 | Medigene Limited | T cell therapies |
| US8216565B2 (en) | 2007-01-12 | 2012-07-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | GP100-specific T cell receptors and related materials and methods of use |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
-
2009
- 2009-07-03 GB GBGB0911566.8A patent/GB0911566D0/en not_active Ceased
-
2010
- 2010-07-01 BR BR112012000107A patent/BR112012000107A2/pt not_active Application Discontinuation
- 2010-07-01 CN CN2010800351402A patent/CN102574906A/zh active Pending
- 2010-07-01 AU AU2010267758A patent/AU2010267758C1/en active Active
- 2010-07-01 CN CN201710535038.2A patent/CN107266560A/zh not_active Withdrawn
- 2010-07-01 DK DK10734524.1T patent/DK2448963T3/da active
- 2010-07-01 EP EP10734524.1A patent/EP2448963B1/en active Active
- 2010-07-01 PT PT107345241T patent/PT2448963E/pt unknown
- 2010-07-01 MX MX2012000155A patent/MX2012000155A/es active IP Right Grant
- 2010-07-01 EA EA201270135A patent/EA026918B1/ru not_active IP Right Cessation
- 2010-07-01 JP JP2012518126A patent/JP5872464B2/ja active Active
- 2010-07-01 ES ES10734524.1T patent/ES2498190T3/es active Active
- 2010-07-01 CN CN201410257886.8A patent/CN104017067B/zh active Active
- 2010-07-01 CA CA2766505A patent/CA2766505C/en active Active
- 2010-07-01 WO PCT/GB2010/001277 patent/WO2011001152A1/en not_active Ceased
-
2011
- 2011-12-22 ZA ZA2011/09522A patent/ZA201109522B/en unknown
-
2012
- 2012-01-03 US US13/342,579 patent/US8519100B2/en active Active
-
2013
- 2013-07-22 US US13/947,580 patent/US9068178B2/en active Active
-
2015
- 2015-10-02 JP JP2015196799A patent/JP6186412B2/ja active Active
-
2022
- 2022-08-15 NL NL301193C patent/NL301193I2/nl unknown
- 2022-08-31 FI FIC20220037C patent/FIC20220037I1/fi unknown
- 2022-09-02 FR FR22C1046C patent/FR22C1046I2/fr active Active
- 2022-09-05 LU LU00278C patent/LUC00278I2/fr unknown